These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18065800)

  • 21. The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects.
    Holven KB; Aukrust P; Retterstøl K; Otterdal K; Bjerkeli V; Ose L; Nenseter MS; Halvorsen B
    J Nutr; 2008 Nov; 138(11):2070-5. PubMed ID: 18936200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
    Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
    Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.
    Vogt L; Laverman GD; van Tol A; Groen AK; Navis G; Dullaart RP
    Nephrol Dial Transplant; 2006 Jan; 21(1):101-6. PubMed ID: 16141462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.
    Niwa T; Katsuzaki T; Miyazaki S; Miyazaki T; Ishizaki Y; Hayase F; Tatemichi N; Takei Y
    J Clin Invest; 1997 Mar; 99(6):1272-80. PubMed ID: 9077536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults.
    Gugliucci A; Kotani K; Taing J; Matsuoka Y; Sano Y; Yoshimura M; Egawa K; Horikawa C; Kitagawa Y; Kiso Y; Kimura S; Sakane N
    Ann Nutr Metab; 2009; 54(3):197-201. PubMed ID: 19420913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Products of advanced glycation in patients with type 2 diabetes and vascular disease.
    Turk Z; Sesto M; Skodlar J; Ferencak G; Pokupec R; Turk N; Stavljenić-Rukavina A
    Ann Clin Biochem; 2003 Sep; 40(Pt 5):552-9. PubMed ID: 14503994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
    Lakshman MR; Gottipati CS; Narasimhan SJ; Munoz J; Marmillot P; Nylen ES
    Metabolism; 2006 Sep; 55(9):1201-6. PubMed ID: 16919539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.
    Boor P; Celec P; Behuliak M; Grancic P; Kebis A; Kukan M; Pronayová N; Liptaj T; Ostendorf T; Sebeková K
    Metabolism; 2009 Nov; 58(11):1669-77. PubMed ID: 19608208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
    Scharnagl H; Stojakovic T; Winkler K; Rosinger S; März W; Boehm BO
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):372-5. PubMed ID: 17701882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products.
    Machado AP; Pinto RS; Moysés ZP; Nakandakare ER; Quintão EC; Passarelli M
    Int J Biochem Cell Biol; 2006 Mar; 38(3):392-403. PubMed ID: 16288898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
    Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
    Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased levels of alpha-defensin (-1, -2 and -3) in type 1 diabetic patients with nephropathy.
    Saraheimo M; Forsblom C; Pettersson-Fernholm K; Flyvbjerg A; Groop PH; Frystyk J;
    Nephrol Dial Transplant; 2008 Mar; 23(3):914-8. PubMed ID: 18003664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced glycosylated end products-mediated activation of polymorphonuclear neutrophils in diabetes mellitus and associated oxidative stress.
    Gupta A; Tripathi AK; Tripathi RL; Madhu SV; Banerjee BD
    Indian J Biochem Biophys; 2007 Oct; 44(5):373-8. PubMed ID: 18341213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
    Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
    Connelly PW
    Nephrol Dial Transplant; 2008 Aug; 23(8):2699-700; author reply 2700. PubMed ID: 18403436
    [No Abstract]   [Full Text] [Related]  

  • 37. Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus.
    Awadallah SM; Saleh SA; Abu Shaqra QM; Hilow H
    J Diabetes Complications; 2008; 22(6):384-8. PubMed ID: 18413152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
    Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
    Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients.
    Hanai K; Babazono T; Yoshida N; Nyumura I; Toya K; Hayashi T; Bouchi R; Tanaka N; Ishii A; Iwamoto Y
    Nephrol Dial Transplant; 2012 Mar; 27(3):1070-5. PubMed ID: 21785041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.